Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)

Immunisation for Adolescents Against Serious Communicable Diseases

This study aims to implement a targeted 4CMenB immunisation program in young people aged 14-19 years in the Northern Territory (NT). As part of the NT program consenting 14-19 year olds will receive 2 doses of the licensed 4CMenB vaccine. An oropharyngeal swab will be collected on the same day as the first dose of the vaccine and 12 months later to assess carriage of Neisseria meningitidis. The first swab will assess baseline carriage prevalence among 14-19 year olds in the NT. The swab taken 12 months later will provide data on the change in carriage that may occur after implementation of the immunisation program. Emerging evidence suggests that the 4CMenB vaccine may be protective against gonorrhea. Therefore, vaccine effect (impact and effectiveness) against both invasive meningococcal disease (IMD) and gonorrhea in the NT will be assessed using data from the above study comparing notifications between vaccinated and unvaccinated as well as comparing pre and post implementation periods.

Study Overview

• Status: Recruiting
• Conditions: Gonorrhea; Meningococcal Disease
• Intervention / Treatment: Biological: Licenced 4CMenB Vaccine

Detailed Description

Meningococcal disease and gonorrhea cause severe morbidity in Australian adolescents, particularly among Aboriginal People. The two diseases are caused by bacteria that are genetically related, but very different in their patterns of transmission and pathogenesis. Bacterial meningitis and sepsis from Neisseria meningitidis (often called meningococcus) can have severe outcomes including long-term disability, arising from neurological deficits and from necrotic skin and gangrene of the limbs requiring amputations. The case fatality rate is ~10%. A multicomponent meningococcal B (4CMenB) vaccine (Bexsero®) is approved and licensed for use against MenB disease in Australia but not funded on the National Immunisation Program (NIP) due to failure to meet cost effectiveness criteria. New emerging data suggest 4CMenB may also protect against gonococcal infection, a sexually transmissible infection (STI) which can infect the urethra, cervix, rectum, conjunctiva, and throat. If left untreated, gonorrhoea can lead to pelvic inflammatory disease, tubal scarring and ultimately infertility in females, and swelling and scarring in the epididymis or testicles in males. In the NT, notification rates for gonorrhoea in 15-19 year olds range from 1924/100,000 to 17,022/100,000 in Aboriginal young people and from 106/100,000 to 1081/100,000 in non-Aboriginal young people over different areas of The Territory (averaged over 2014-2018). At present there is no vaccine against gonorrhoea. Emerging evidence shows that the 4CMenB vaccine may have some protection against gonorrhoea due to genetic similarities that exist between the two organisms that cause meningitis and gonorrhoea. If the effectiveness of the 4CMenB vaccine against gonorrhoea can be demonstrated at a population level it would have substantial health benefits to be gained world-wide, but particularly for Aboriginal People.

Consenting 14-19 year olds will be asked to complete a 1-2 page questionnaire to collect information on risk factors for meningococcal disease and meningococcal carriage. A throat swab will be obtained and the first dose of the 4CMenB vaccine will be administered. Two-three months after the first dose, participants will receive the second dose of the 4CMenB vaccine. One year after the first dose, the participants will be asked to come for the third visit, where they will be asked to complete the same questionnaire that was completed during visit one and a throat swab taken. Throat swabs will be tested to detect the meningococcus bacteria which is carried in the throat of around 10% of people. Research in South Australia has shown double the rates of carriage in Aboriginal People compared to non-Aboriginal People.

The effectiveness of the 4CMenB vaccine against meningococcal carriage, invasive meningococcal disease and gonorrhoea will be evaluated using results of meningococcal carriage and routine surveillance data on IMD and gonorrhoea obtained from the Centre for Disease Control (CDC), the data custodian for notifiable diseases in the NT. The evaluations will include comparisons between vaccinated vs unvaccinated and number of notifications in post vs pre study implementation periods. The data on IMD and gonorrhoea notifications in the NT will be obtained from the Communicable Disease Control in the NT. The main methodological approaches involve an Interrupted Time Series regression model, screening approaches, and case-control analyses with different sets of controls to estimate vaccine impact and effectiveness

• Study Type: Observational
• Enrollment (Anticipated): 7100

Contacts and Locations

• Study Contact: Name: Helen Marshall, MBBS,MD,MPH; Phone Number: +61 8 8161 8115; Email: helen.marshall@adelaide.edu.au
• Study Contact Backup: Name: Prabha Andraweera, MBBS,PhD; Phone Number: +61 8 8161 8117; Email: prabha.andraweera@adelaide.edu.au

Study Locations

• Australia
  • Central Australia, Australia
    • Recruiting
    • Northern Territory
    • Contact: Helen Marshall

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 19 years (Child, Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

All consenting 14-19-year-olds residing in the Northern Territory who do not have any of the above exclusion criteria

Description

Inclusion Criteria:

All consenting 14-19 year olds residing in the Northern Territory in 2020-2021

Exclusion Criteria:

• Anaphylaxis following any component of Bexsero® vaccine
• Previous receipt of MenB vaccine (Bexsero® (Previous receipt of MenNZBTM is allowed).
• Known pregnancy
• Clinical conditions representing a contraindication to intramuscular vaccination and venipuncture
• Any clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
14-19 year olds residing in the Northern Territory; All consenting 14-19 year olds residing in the Northern Territory in 2020-2021	Biological: Licenced 4CMenB Vaccine; Two doses (0.5 mL each) of Bexsero ® vaccine at least 2 months apart to be given to consenting 14-19 year olds

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effect of 4CMenB vaccine on carriage of all N.meningitidis	Prevalence of all N. meningitidis in the pharynx among 14-19 year olds as measured by PCR at baseline compared to 12 months	12 months
1. 4CMenB vaccination status in the population with gonorrhoea compared to randomly selected Chlamydia controls (Case-control)	Vaccination status among 15-19 year olds diagnosed with gonorrhoea compared to vaccination status of 15 - 19 year olds diagnosed with Chlamydia	3 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effect of 4CMenB vaccine on carriage of all disease causing N.meningitidis	Prevalence of all disease-causing genogroup of N. meningitidis (A, B, C, E, X, W, Y) by PCR at baseline and at 12 months	12 months
Effect of 4CMenB vaccine on carriage of each disease causing N.meningitidis	Prevalence of each disease-causing genogroup of N. meningitidis (A, B, C, E, X, W, Y) by PCR at baseline and at 12 months	12 months
Effect of 4CMenB vaccine on carriage of all non-groupable N.meningitidis	Prevalence of all non groupable N. meningitidis at baseline and at 12 months	12 months
Effect of 4CMenB vaccine on acquisition of all N. meningitidis	Acquisition of all N. meningitidis (negative at baseline, positive at 12-month follow-up) as measured by PCR	12 months
Effect of 4CMenB impact on Group B IMD (Interrupted time series)	Notifications of group B IMD (invasive meningococcal disease) in the 4CMenB vaccinated population compared to the unvaccinated population and in years preceding 4CMenB vaccination compared to post vaccination (Interrupted time series analysis).	3 years
Effect of 4CMenB effectiveness on Group B IMD (screening method)	4CMenB vaccination status in the population with IMD, compared to the general population (Screening method) and compared to randomly selected controls (Case-control method).	3 years
Effect of 4CMenB effectiveness on Group B IMD (case-control method)	4CMenB vaccination status in the population with IMD, compared to the general population (Screening method) and compared to randomly selected controls (Case-control method).	3 years
Risk factors for gonorrhoea	Risk factors associated with gonorrhoea in 15-19 year olds	12 months
Risk factors for carriage of all N.meningitidis	Risk factors associated with carriage of all genogroups of N. meningitidis in 14 -19 year olds at baseline and 12 months	12 months
Risk for carriage of disease causing genogroups of N.meningitidis	Risk factors associated with carriage of disease-causing genogroups of N. meningitidis (A, B, C, E, W, X, Y) in 14 -19 year olds at baseline and 12 months	12 months
Cost effectiveness of the 4CMenB vaccine	Cost of meningococcal disease (acute care and management of sequelae up to one year) and cost of treatment of gonorrhoea compared to cost of 4CMenB vaccine	3 years
4CMenB vaccination status in the population with gonorrhoea compared to randomly selected controls from the Australian Immunisation Register (Case-control)	4CMenB vaccination status among 15-19 year olds diagnosed with gonorrhoea compared to controls from the Australian Immunisation register	3 years
4CMenB vaccination status in the population with gonorrhoea compared to the general population (Screening method)	4CMenB vaccination status among 15-19 year olds diagnosed with gonorrhoea compared to the general population	3 years
All laboratory confirmed notifications of gonorrhoea in the six years preceding 4CMenB vaccination compared to three years post vaccination (Interrupted time series analysis)	Laboratory confirmed notifications of gonorrhoea in years preceding 4CMenB vaccination compared to post vaccination	7 years
All laboratory confirmed notifications of gonorrhoea in 15-19 year olds in the vaccinated population compared to the unvaccinated population	Gonorrhoea notifications in vaccinated vs unvaccinated	3 years
All laboratory confirmed notifications of gonorrhoea in the vaccinated population compared to the unvaccinated population stratified by gender	Gonorrhoea notifications in vaccinated vs unvaccinated (stratified by gender)	3 years
All laboratory confirmed notifications of gonorrhoea in the vaccinated population compared to the unvaccinated population stratified by geographical location (regional/remote/very remote)	Gonorrhoea notifications in vaccinated vs unvaccinated stratified by location	3 years

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Whole genome sequencing of all carriage isolates	Description of whole genome sequencing of all carriage isolates	12 months
Whole genome sequencing of all disease causing carriage isolates	Description of Whole genome sequencing of all disease causing carriage isolates	12 months
Awareness of STIs and STI testing among young adults	Proportion of 14 -19 year olds who undergo STI testing after implementation of the program compared to 12 months pre implementation	12 months

Collaborators and Investigators

• Sponsor: University of Adelaide
• Collaborators: University of Sydney; The University of New South Wales; Menzies School of Health Research; The University of Queensland; The University of Western Australia; Northern Territory Government of Australia; SA Health

Publications and helpful links

General Publications

• Marshall HS, Andraweera PH, Ward J, Kaldor J, Andrews R, Macartney K, Richmond P, Krause V, Koehler A, Whiley D, Giles L, Webby R, D'Antoine H, Karnon J, Baird R, Lawrence A, Petousis-Harris H, De Wals P, Greenwood-Smith B, Binks M, Whop L. An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia-Study Protocol. Vaccines (Basel). 2022 Feb 16;10(2):309. doi: 10.3390/vaccines10020309.

Study record dates

Study Major Dates

• Study Start (Actual): March 4, 2021
• Primary Completion (Anticipated): December 31, 2024
• Study Completion (Anticipated): December 31, 2024

Study Registration Dates

• First Submitted: May 18, 2020
• First Submitted That Met QC Criteria: May 18, 2020
• First Posted (Actual): May 21, 2020

Study Record Updates

• Last Update Posted (Estimate): March 9, 2023
• Last Update Submitted That Met QC Criteria: March 7, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Sexually Transmitted Diseases; Disease Attributes; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Neisseriaceae Infections; Sexually Transmitted Diseases, Bacterial; Infections; Communicable Diseases; Meningococcal Infections; Gonorrhea
• Other Study ID Numbers: Menzies HREC/2019-3507-V1.7

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: De-identified, individual participant data underlying published results will be available
• IPD Sharing Time Frame: We estimate the data will be available from the start of 2025 for approximately 12 months
• IPD Sharing Access Criteria: IPD will be made available on a case-by-case basis at the discretion of the International Scientific Advisory Committee and The NT Department of Health and Menzies School of Health Research and the Central Australian HREC. IPD data will only be available to achieve the aims in the approved proposal
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No